Colorado offering $14,000 hiring bonuses to mental health 16-03-2023, 00:23

Hivello’s “Buy Back & Burn” Initiative to Support $HVLO Growth & Sustainability 28-05-2025, 20:30

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00